Geneuro SA GNRO.PA
€0.03 €0.00 (0.65%) 1D
Last Updated: Jan 22, 12:00 AM·XPAR
Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
GNRO.PA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: September 12, 2024
Report Source: 2023 Annual Report
Geneuro SA. Stock Analysis GNRO.PA
France Health Care Nano Cap Report: GeNeuro SA engages in the research and development of treatments against neurological disorders and autoimmune disease. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Read More Geneuro SA (GNRO.PA) Chart
Key Statistics of Geneuro SA (GNRO.PA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€0.03Volume
67.72KP/E Ratio (TTM)
-52 Week Range
Market Cap
920.00KAvg. Volume
148.93KDividend Yield
-Financial Metrics & Statements of Geneuro SA (GNRO.PA)
FAQ's for Geneuro SA (GNRO.PA)
- According to Musaffa’s Shariah screening methodology, Geneuro SA (GNRO.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Geneuro SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in Geneuro SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Geneuro SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Geneuro SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Geneuro SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.